2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1139

Pyogenic Arthritis: Clinical and Epidemiological Features Of 101 Cases At a University Hospital
Abstract Number: 2109

Quality Indicators For Physical Therapy Management In Hip and Knee Osteoarthritis and Rheumatoid Arthritis
Abstract Number: 1936

Quality Of Care In Patients At Risk For Pulmonary Involvement: Assessment Of Pulmonary Screening In Systemic Sclerosis and Myositis Patients In a General Rheumatology Clinic
Abstract Number: 2662

Quality Of Care Predicts Disease Outcomes Among Patients With Systemic Lupus Erythematosus
Abstract Number: 1908

Quality Of Life and Adherence To Treatment In Patients Managed In Nursing Clinics In Rheumatology
Abstract Number: 1104

Quality Of Life and Burden Of Ehlers-Danlos Syndrome (EDS) Type III
Abstract Number: 2605

Quality Of Life and Psychosocial Aspects In Juvenile Localized Scleroderma
Abstract Number: 1029

Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Abstract Number: 2461

Quality Of Life, Physical Function and Symptoms In Non-Radiographic Axial Spondyloarthritis:The Patient Perspective
Abstract Number: 1015

Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Ankylosing Spondylitis Patients In The Czech Republic
Abstract Number: 995

Quality Of Life, Productivity Impairment, Disease Severity and Health Care Costs In Relation To Functional Impairment In Psoriatic Arthritis Patients In The Czech Republic
Abstract Number: 316

Quantiferon-TB Test Can Be Usefull For Decision Of Anti-Tuberculosis Prophylaxis During Anti-TNF Treatment: Result Of Real Life
Abstract Number: 1119

Quantification Of Inflammatory Disease Of Spine In Ankylosing Spondylitis Using Volumetric Magnetic Resonance Imaging Analysis
Abstract Number: 678

Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 2309

Quantifying The Gap Between General Population Guidelines and Expert Opinion For Cardiovascular Risk Management In Rheumatic Disease Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].